// OVERVIEW
Global pharmaceutical company with major franchises in diabetes, oncology, and immunology.
Discussed in
- Decacorns are the new unicorns
- 💡 Army of agents
- Biotech IPOs get their groove back
- SpaceX builds a lockup ladder
- OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze
- Microsoft sets OpenAI free
- Axios Pro Rata_ Kushner plays ball
- Eli Lilly's $7B hedge against GLP-1s
// RECENT MENTIONS
// SIGNALS
19 SIGNALS
01
mention·PitchBook News·JULY 27, 2026
“Total value reached a record $34.4 billion in Q2... Eli Lilly, most notably, was flush with cash from the GLP-1 boom.”
Source→02
funding·Lucinda Shen·JULY 21, 2026
“Scribe Therapeutics...plans to raise up to $108m in an IPO...It's raised $121m from a16z, Avoro Ventures, Eli Lilly, OrbiMed, T. Rowe Price, Perceptive Advisors, Wellington Management, RA Capital Management, and Menlo Ventures.”
03
product·Lucinda Shen·JULY 15, 2026
“Oura — Smart ring maker — Received a strategic investment from Eli Lilly”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.